IL6 and lymphopenia: Among laboratory biomarkers, increased serum C-reactive protein (CRP), ferritin, D-dimer, and interleukin 6 (IL-6) levels, as well as leucocytosis, neutrophilia, lymphocytopenia, elevated neutrophil-to-lymphocyte ratio, and thrombocytopenia have been associated with MIS in Stages 2b-3, and also with the outcome of COVID-19 [5,6,8].